Publications

CendR Platform™ Technology

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Dean A., et al. The Lancet Gastroenterology and Hepatology. 2022; https://doi.org/10.1016/S2468-1253(22)00167-4

Tumor Microenvironment-Responsive Polymeric iRGD and Doxorubicin Conjugates Reduce Spontaneous Lung Metastasis in an Orthotopic Breast Cancer Model

Peng Z-H, Jogdeo CM, Li J, Xie Y, et al. Pharmaceutics. 2022; 14(8):1725. https://doi.org/10.3390/pharmaceutics14081725

Nature Communications: Tumor-penetrating therapy for ß5 integrin-rich pancreas cancer

Hurtado de Mendoza, T., Mose, E.S., Botta, G.P. et al. Nat Communications 12, 1541. 2021; https://doi.org/10.1038/s41467-021-21858-1

Molecular Cancer Therapeutics: iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer

Lo JH, Hao L, Muzumdar MD, et al. Mol Cancer Ther. 2018;17(11):2377-2388. doi: 10.1158/1535-7163.MCT-17-1090

Cancer Research: Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

Fan Zhang, Sirkka B. Stephan, et al. Cancer Res. 2018; 78 (13): 3718–3730. https://doi.org/10.1158/0008-5472.CAN-18-0306

The Journal of Clinical Investigation: Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer

Liu X, Lin P, Perrett I, et al. J Clin Invest. 2017;127(5):2007-2018. doi: 10.1172/JCI92284

Advanced Drug Delivery Reviews: Tumor penetrating peptides for improved drug delivery

Ruoslahti E. Adv Drug Deliv Rev. 2017;110-111:3-12. doi: 10.1016/j.addr.2016.03.008

Nature Communications: In vivo cation exchange in quantum dots for tumor-specific imaging

Liu, X., Braun, G.B., Qin, M. et al. Nat Communications 8, 343. 2017. https://doi.org/10.1038/s41467-017-00153-y

Cancer Research: Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

Christian Schmithals, Verena Köberle, et al. Cancer Res. 2015; 75 (15): 3147–3154. https://doi.org/10.1158/0008-5472.CAN-15-0395

British Journal of Cancer: Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1

Akashi, Y., Oda, T., et al. British journal of cancer, 110(6), 1481–1487. 2014. https://doi.org/10.1038/bjc.2014.49

Science: Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

Ruoslahti E, et al. Science. 2010; 28, 5981. doi: 10.1126/science.1183057

CD34+ Cell Technology

Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease

Luu, Judy M, Wei, Janet, Bairey Merz, C. Noel, et al. 2022. Journal of the American Heart Association. https://doi.org/10.1161/JAHA.121.022573

Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction

Henry, T. D., Bairey Merz, C. N., et al. Circulation. 2022. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010802

Transplantation of CD34+ cells for myocardial ischemia

Matta A, Nader V, Galinier M, Roncalli J. Transplantation of CD34+ cells for myocardial ischemia. World J Transplant 2021; 11(5): 138-146.

Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair—A Systematic Review

Rai, B., Shukla, J., Henry, T. D., & Quesada, O. (2021). Published in cells.

Testing for Coronary Microvascular Dysfunction

Bairey Merz CN. JAMA. Published online November 18, 2019. doi

CD34+ Cell Therapy Significantly Reduces Adverse Cardiac Events, Health Care Expenditures, and Mortality in Patients with Refractory Angina

Johnson, GL, Henry, TD, Povsic, TJ, et al. STEM CELLS Transl Med. 2020; 1– 6.

Autologous CD34+ Cell Therapy for Ischemic Tissue Repair

Sietsema W.K., et al. (2019).

CD34+ cell therapy for no option refractory disabling angina: Time for FDA approval?

Lillian Benck, Timothy D. Henry, Carrev (2019),

Japan’s Conditional Approval Pathway for Regenerative Medicines

Sietsema W.K., et al. (2018.) Regulatory Focus. Regulatory Affairs Professionals Society.

Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials

Henry, T.D., et al. (2018.); European Heart Journal, , ehx764,

Coronary Microvascular Dysfunction― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy

Chen, C., Wei, J., AlBadri, A., Zarrini, P., & Bairey Merz, N. (2016). Circulation Journal, 81(1), 3-11. doi:

PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI

Quyyumi A., et al. (2016.) Circulation Research, 119(10).

Coronary Microvascular Dysfunction, Microvascular Angina, and Management

Löffler, A. I., & Bourque, J. M. (2016). Current cardiology reports, 18(1), 1.

Long-term Clinical Outcome after Intracoronary Application of Bone Marrow-derived Mononuclear Cells for Acute Myocardial Infarction: Migratory Capacity of Administered Cells Determines Event-free Survival

Assmus, B., et al. (2014.) European Heart Journal, 35(19):1275-83.

Short- and Long-term Outcomes of Intracoronary and Endogenously Mobilized Bone Marrow Stem Cells in the Treatment of ST-segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Control Trials

Zimmet, H., et al. (2012.) European Journal of Heart Failure, 14(1), 91–105.

Phase II Clinical Trial of CD34+ Cell Therapy to Explore Endpoint Selection and Timing in Patients with Critical Limb Ischemia

Fujita, Y., et al. (2014.) Circulation Journal, 78(2): 490- 501.

Impact of Intracoronary Bone Marrow Cell Therapy on Left Ventricular Function in the Setting of ST-segment Elevation Myocardial Infarction: A Collaborative Meta-analysis

Delewi, R., et al. (2014.) European Heart Journal, 35(15):989-98.

A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia

Losordo, D., et al. (2012.) Circ Cardiovasc Interv, 5 (6): 821-30.

Long-term Clinical Outcome after Intramuscular Transplantation of Granulocyte Colony Stimulating Factor-mobilized CD34 Positive Cells in Patients with Critical Limb Ischemia

Kinoshita, M., et al. (2012.) Atherosclerosis, 224(2): 440-45.

Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Clinical Trials

Delewi, R., et al. (2012). Heart (British Cardiac Society).

Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges

Tongers, J., Losordo, D. W., & Landmesser, U. (2011). European heart journal, 32(10), 1197–1206.

CD34-positive stem cells: in the treatment of heart and vascular disease in human beings

Mackie, A. R., & Losordo, D. W. (2011). Texas Heart Institute journal, 38(5), 474–485.

Intramuscular Transplantation of G-CSF-mobilized CD34(+) Cells in Patients with Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-blinded, Dose-escalation Clinical Trial

Kawamoto, A., et al. (2009) Stem Cells, 27 (11), 2857-64.

Improved Clinical Outcome after Intracoronary Administration of Bone-marrow-derived Progenitor Cells in Acute Myocardial Infarction: Final 1-year Results of the REPAIR-AMI Trial

Schächinger, V., et al. (2006) European Heart Journal, 27(23), 2775–83.

Related Cardiovascular Publications

Contemporary Management of Refractory Angina

Lantz, R., et. al. (2022). Contemporary Management of Refractory Angina. Interventional cardiology clinics, 11(3), 279–292. https://doi.org/10.1016/j.iccl.2022.03.002

Definition and epidemiology of coronary microvascular disease

Bradley, C., Berry, C. Definition and epidemiology of coronary microvascular disease. J. Nucl. Cardiol. (2022). https://doi.org/10.1007/s12350-022-02974-x

IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries

Corban MT, et al., Circ Res. (2021) doi: 10.1161/CIRCRESAHA.121.319644

Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Gender in CV Medicine

Mehta PK, Wei J, Shufelt C, Quesada O, Shaw L and Bairey Merz CN (2021) Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Gender in CV Medicine. Front. Cardiovasc. Med. 8:744788. doi: 10.3389/fcvm.2021.744788

Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis

Mihir A Kelshiker, on behalf of the Coronary Flow Outcomes reviewing committee, Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis, European Heart Journal, 2021;, ehab775, https://doi.org/10.1093/eurheartj/ehab775

Pathophysiology of Coronary Microvascular Dysfunction

Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular Dysfunction. Circ J. 2021 Nov 9. doi: 10.1253/circj.CJ-21-0848. Epub ahead of print. PMID: 34759123.

Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases

Montone, R. et al., (2021) Journal of the American College of Cardiology

Patient Perspective: Maria George founder of INOCA International

Judith Ozkan, Patient Perspective: Maria George founder of INOCA International: How can patients and physicians work together to ease the impact of heart disease? CardioPulse talks to former civil servant turned campaigner Maria George about why she established the patient partnership group INOCA International., European Heart Journal, 2021;

Treatment of coronary microvascular dysfunction

Bairey Merz, C. N, et al. (2020) Cardiovascular Research, Volume 116, Issue 4, 15 , Pages 856–870.

1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA)

Ford TJ, et al. JACC Cardiovasc Interv. 2020

Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies.

Gallone, et al. (2020) JACC: Cardiovascular Interventions, Volume 13, Issue 1, 13 January 2020, Pages 1-19.

More Data Than Options for the “No-Option” Refractory Angina Patient in the United States

Riley, F. R, et al. (2019) Circulation. 124:1689–1691.

How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial

Ford, TJ, et al. (2019) Interventional Cardiology Review. 14(2):76–82. DOI:

Stem Cells in the Treatment of Disease

Blau, M. H, et al. (2019) N Engl J Med. 380:1748-1760. DOI: 10.1056/NEJMra1716145

The Impact of Cell Therapy on Cardiovascular Outcomes in Patients With Refractory Angina

Jones, A. D, et al. (2019). Circulation, Volume 124, Issue 12, 7 June 2019, Pages 1786-1795

Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review

Taqueti VR, et al. J Am Coll Cardiol. 2018; doi:10.1016/j.jacc.2018.09.042

Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

Bairey Merz, C. N., et al. (2017). Circulation, 135(11), 1075–1092.

Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease

Taqueti VR, et al. Circulation. 2017; doi:10.1161/CIRCULATIONAHA.116.023266

Treatment of angina and microvascular coronary dysfunction

C, Bairey Merz CN, et al. Curr Treat Options Cardiovasc Med. 2010 Aug;12(4):355-64. doi: 10.1007/s11936-010-0083-8. PMID: 20842559; PMCID: PMC3914311.

CendR Platform™ Technology

CD34+ Cell Technology

Related Cardiovascular Publications

Commentary